Biocon Ltd - Sep 12, 2024 Form 3 Insider Report for Bicara Therapeutics Inc. (BCAX)

Role: 10%+ Owner
Signature: BIOCON LIMITED, By: /s/ Kiran Mazumdar-Shaw, Title: Executive Chairperson
Stock symbol: BCAX
Transactions as of: Sep 12, 2024
Transactions value $: $0
Form type: 3
Date filed: 9/12/2024, 09:00 PM
Next filing: Sep 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	BCAX	Common Stock						116K	Sep 12, 2024	By Biocon Limited	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	BCAX	Series Seed Redeemable Convertible Preferred Stock							Sep 12, 2024	Common Stock	4.33M		By Biocon Limited	F1, F2
holding	BCAX	Series Seed Redeemable Convertible Preferred Stock							Sep 12, 2024	Common Stock	1.08M		By Biocon Pharma Inc.	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Shares held by Biocon Limited ("Biocon Ltd"). Kiran Mazumdar-Shaw is the managing member of Biocon Ltd. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.
F2	Each share of Series Seed Redeemable Convertible Preferred Stock (the "Preferred Stock") is convertible into Common Stock on a 9.2435-to-one basis at the option of the holder, and will convert automatically upon closing of the Issuer's initial public offering into the number of shares shown in column 3 without payment of consideration. The Preferred Stock has no expiration date.
F3	Shares held by Biocon Pharma Inc. ("Biocon Pharma"). Kiran Mazumdar-Shaw is the managing member of Biocon Pharma. Each of the Reporting Persons and Ms. Mazumdar-Shaw disclaims beneficial ownership of such shares for purposes of Section 16 of the Exchange Act, except to the extent of her or its pecuniary interest therein, if any. This report shall not be deemed an admission that any Reporting Person is a beneficial owner of such shares for the purpose of Section 16 of the Exchange Act, or for any other purpose.